SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report

被引：1

作者：

Medwid, Samantha ^{[1
]}

Deckert, Rowan ^{[1
]}

Gryn, Steven E. ^{[1
,2
]}

Kim, Richard B. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Western Ontario, Dept Med, London, ON, Canada

[2] London Hlth Sci Ctr, London, ON, Canada

[3] Western Univ, Dept Physiol & Pharmacol, London, ON, Canada

[4] Lawson Hlth Res Inst, London, ON, Canada

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2025年 / 91卷 / 01期

关键词：

statins; rhabdomyolysis; pharmacogenetics; DRUG; POLYMORPHISMS; TRANSPORTERS;

D O I：

10.1111/bcp.16329

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We report a case of an adult woman of African ancestry who was hospitalized with statin induced- rhabdomyolysis. The patient presented to the emergency room with a 2-week history of worsening muscle pain, nausea, vomiting and low oral intake, 1 month after starting 40 mg daily dose of rosuvastatin. Sequencing of SLCO1B1 coding regions revealed the patient was heterozygous for two SLCO1B1 deleterious variants, c.481+1G>T and c.1463G>C (*9), which are more prevalent in patients of African ancestry. This highlights the importance of pharmacogenetic testing in SLCO1B1, which includes a broader range of genetic variants for patients of African ancestry.

引用

页码：232 / 235

页数：4

共 50 条

[31] Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin
Zhang, Dan
Ding, Yangming
Wang, Xiaoxue
Xin, Wenyu
Du, Wenwen
Chen, Wenqian
Zhang, Xianglin
Li, Pengmei
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (07) : 939 - 946
[32] Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin
Dan Zhang
Yangming Ding
Xiaoxue Wang
Wenyu Xin
Wenwen Du
Wenqian Chen
Xianglin Zhang
Pengmei Li
European Journal of Clinical Pharmacology, 2020, 76 : 939 - 946
[33] Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Ramsey, Laura B.
Bruun, Gitte H.
Yang, Wenjian
Trevino, Lisa R.
Vattathil, Selina
Scheet, Paul
Cheng, Cheng
Rosner, Gary L.
Giacomini, Kathleen M.
Fan, Yiping
Sparreboom, Alex
Mikkelsen, Torben S.
Corydon, Thomas J.
Pui, Ching-Hon
Evans, William E.
Relling, Mary V.
GENOME RESEARCH, 2012, 22 (01) : 1 - 8
[34] Genetic variants in the human SLCO1B1 gene and individual variations in methotrexate clearance
Ishikawa, Toshihisa
PHARMACOGENOMICS, 2012, 13 (09) : 993 - 994
[35] SLCO1B1 linked to commonly prescribed simvastatin and induced myopathy
Baryan, Hardaman
PHARMACOGENOMICS, 2012, 13 (09) : 991 - 991
[36] SLCO1B1 Variants and Urine Arsenic Metabolites in the Strong Heart Family Study
Gribble, Matthew O.
Voruganti, Venkata Saroja
Cropp, Cheryl D.
Francesconi, Kevin A.
Goessler, Walter
Umans, Jason G.
Silbergeld, Ellen K.
Laston, Sandra L.
Haack, Karin
Kao, Wen Hong Linda
Fallin, Margaret Daniele
MacCluer, Jean W.
Cole, Shelley A.
Navas-Acien, Ana
TOXICOLOGICAL SCIENCES, 2013, 136 (01) : 19 - 25
[37] Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations
Jessica Mwinyi
Karla Köpke
Melanie Schaefer
Ivar Roots
Thomas Gerloff
European Journal of Clinical Pharmacology, 2008, 64 : 257 - 266
[38] Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations
Mwinyi, Jessica
Koepke, Karla
Schaefer, Melanie
Roots, Ivar
Gerloff, Thomas
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) : 257 - 266
[39] SLCO1B1 variants and the risk of antituberculosis drug-induced hepatotoxicity: a systematic review and meta-analysis
Zhu, Min
Chen, Xinyu
Hao, Zhuolu
He, Yiwen
Han, Bing
Tang, Shaowen
PHARMACOGENOMICS, 2023, 24 (18) : 931 - 942
[40] SLCO1B1*5 behind statin-induced adverse effects
Reactions Weekly, 2009, 1277 (1) : 4 - 4

← 1 2 3 4 5 →